First, molecular analysis of BC revealed that the disease was composed of different subtypes with distinct survival outcomes [8,9], including HER2-positive and triple-negative BC, two subtypes in which both survival benefits from adjuvant chemotherapy and probability of reaching pCR after NAC are the highest. The gene discussed is ERBB2; the disease is breast cancer.